PrevenTron trial tests trontinemab to prevent Alzheimer's
Analysis based on 12 articles · First reported Sep 04, 2026 · Last updated Sep 05, 2026
Positive sentiment for Roche as trontinemab could become a preventive treatment for Alzheimer's, a large market. The trial's success could also boost the broader Alzheimer's drug market and diagnostic testing, while existing drugs like lecanemab and donanemab face competition.
The PrevenTron phase III clinical trial, led by United Kingdom — Cornwall Partnership NHS Foundation Trust in the UK, will test whether the experimental Alzheimer's drug trontinemab, developed by Roche, can prevent dementia in healthy middle-aged adults who show elevated levels of the p-tau217 biomarker but have no memory problems. The trial will recruit about 1,600 participants aged 55-80 internationally, with the first European screenings beginning in Britain. Participants will be randomly assigned to receive trontinemab or a placebo and monitored for four to six years. Trontinemab uses a 'brain shuttle' mechanism to cross the blood-brain barrier and clear amyloid plaques more rapidly than existing drugs like lecanemab and donanemab. The trial represents a shift from treating symptoms to prevention, potentially enabling a 'statins for the brain' approach. The Alzheimer s Society and Daily Mail have partnered in a Defeating Dementia campaign to raise awareness and support research.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard